<p>礼来公司（NYSE:LLY - 获取免费报告）在周三向客户和投资者发布的研究报告中，Guggenheim 的股票研究人员将其目标价格从 942.00 美元下调至 875.00 美元。该公司目前对该股票的评级为 “买入”。Guggenheim 的价格目标暗示该公司当前价格有 35.69% 的潜在上涨空间。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
</ul>
<p>其他股票研究分析师最近也对该股票发布了报告。Erste Group Bank 在 6 月 5 日的研究报告中将礼来公司的股票评级从 “买入” 下调至 “持有”。汇丰全球研究在 4 月 28 日的研究报告中将礼来公司的股票评级从 “强力买入” 下调至 “适度卖出”。华尔街 Zen 在 7 月 26 日的报告中将礼来公司的股票评级从 “持有” 上调至 “买入”。Leerink Partners 在 8 月 7 日的报告中重申了 “市场表现” 评级，并对礼来公司的股票设定了 715.00 美元的目标价格。最后，Cantor Fitzgerald 在 4 月 22 日的报告中开始覆盖礼来公司的股票。他们给予了 “增持” 评级，并设定了 975.00 美元的目标价格。一位研究分析师对该股票给予了卖出评级，五位分析师给予了持有评级，十六位分析师给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 973.71 美元。</p>
<p><strong>查看我们关于 LLY 的最新研究报告</strong></p>
<h2>礼来公司股价上涨 0.8%</h2>
<ul>
<li>礼来公司 14% 的财报后下滑是否是买入机会？</li>
</ul>
<p>礼来公司的股票在周三开盘价为 644.86 美元。该公司的 50 日简单移动平均线为 769.64 美元，200 日简单移动平均线为 797.19 美元。礼来公司的 52 周低点为 623.78 美元，52 周高点为 972.53 美元。该公司的速动比率为 1.00，流动比率为 1.28，债务股本比率为 1.86。该公司的市值为 6103.3 亿美元，市盈率为 42.30，PEG 比率为 0.89，贝塔值为 0.44。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）最后一次公布季度财报是在 8 月 7 日。该公司报告每股收益（EPS）为 6.31 美元，超出分析师的共识预期 5.59 美元，超出幅度为 0.72 美元。礼来公司的净利润率为 25.91%，股本回报率为 92.72%。该公司在本季度的收入为 155.6 亿美元，而共识预期为 144.0 亿美元。去年同期，该公司每股收益为 3.92 美元。与去年同期相比，该公司的收入增长了 37.6%。整体来看，股票分析师预测礼来公司在当前财政年度将发布 23.48 美元的每股收益。</p>
<h2>内部买卖情况</h2>
<ul>
<li>诺和诺德股票下跌——但底部是否终于到来？</li>
</ul>
<p>在其他新闻中，董事 J Erik Fyrwald 在 8 月 12 日的交易中购买了 1565 股该公司的股票。该股票的平均购买价格为每股 642.33 美元，总价值为 1,005,246.45 美元。交易完成后，该董事直接持有 74,578 股该公司的股票，价值约为 47,903,686.74 美元。这笔交易代表了他们持股比例的 2.14% 的增加。该收购在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，执行副总裁 Daniel Skovronsky 在 8 月 12 日的交易中购买了 1000 股该公司的股票。该股票的平均购买成本为每股 634.40 美元，总价值为 634,400.00 美元。收购后，该执行副总裁直接持有 137,660 股该公司的股票，价值约为 87,331,504 美元。这笔交易使他们的持股比例增加了 0.73%。该购买的披露信息可以在此找到。在过去 90 天内，内部人士共购买了 4,514 股公司股票，价值为 2,894,841 美元。目前，0.14% 的股票由公司内部人士持有。</p>
<h2>礼来公司的机构交易情况</h2>
<p>几家大型投资者最近调整了他们在 LLY 的持股。Tobias Financial Advisors Inc.在第四季度将其在礼来公司的持股增加了 4.1%。Tobias Financial Advisors Inc.目前持有 307 股该公司的股票，价值 237,000 美元，此前在上个季度增加了 12 股。Redwood Investments LLC 在第四季度将其在礼来公司的持股增加了 0.5%。Redwood Investments LLC 目前持有 2209 股该公司的股票，价值 1,705,000 美元，此前在此期间购买了 12 股。Hobbs Wealth Management LLC 在第一季度将其在礼来公司的持股增加了 0.8%。Hobbs Wealth Management LLC 目前持有 1459 股该公司的股票，价值 1,205,000 美元，此前在此期间购买了 12 股。Hixon Zuercher LLC 在第一季度将其在礼来公司的持股增加了 0.7%。Hixon Zuercher LLC 目前持有 1789 股该公司的股票，价值 1,477,000 美元，此前在此期间购买了 12 股。最后，O Brien Wealth Partners LLC 在第一季度将其在礼来公司的持股增加了 25.5%。O Brien Wealth Partners LLC 目前持有 59 股该公司的股票，价值 49,000 美元，此前在此期间购买了 12 股。机构投资者和对冲基金持有该公司 82.53% 的股票。</p>
<h2>关于礼来公司</h2>
<p>（获取免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比礼来公司更好的股票</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>数据中心需求旺盛——这家 REIT 拥有整个投资组合</li>
<li>3 只引领迷因股复兴的股票</li>
<li>3 只值得在未来十年内买入并持有的电池股票</li>
<li>什么是微型股？您需要知道的一切</li>
<li>在能源市场紧张局势加剧时值得考虑的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在您考虑礼来公司之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Guggenheim 将礼来公司（NYSE: LLY）的目标价格从 942.00 美元下调至 875.00 美元，同时维持 “买入” 评级。这个新目标暗示从当前价格来看有 35.69% 的潜在上涨空间。其他分析师的意见各不相同，有些下调了评级，而另一些则维持或提高了评级。礼来的股票开盘价为 644.86 美元，市场共识评级为 “适度买入”，目标价格为 973.71 美元。该公司报告了强劲的季度收益，收入同比增长 37.6%，超出预期</p>

<p>Eli Lilly and Company (NYSE:LLY - Get Free Report) had its target price dropped by equities researchers at Guggenheim from $942.00 to $875.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Guggenheim's price objective would suggest a potential upside of 35.69% from the company's current price.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）在周三向客户和投资者发布的研究报告中，Guggenheim 的股票研究人员将其目标价格从 942.00 美元下调至 875.00 美元。该公司目前对该股票的评级为 “买入”。Guggenheim 的价格目标暗示该公司当前价格有 35.69% 的潜在上涨空间。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
</ul>
</div><p>Other equities research analysts have also recently issued reports about the stock. Erste Group Bank cut shares of Eli Lilly and Company from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, June 5th. Hsbc Global Res cut shares of Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;moderate sell&#34; rating in a research report on Monday, April 28th. Wall Street Zen raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, July 26th. Leerink Partners reaffirmed a &#34;market perform&#34; rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an &#34;overweight&#34; rating and a $975.00 target price for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $973.71.</p>
<div class="lb-trans"><p>其他股票研究分析师最近也对该股票发布了报告。Erste Group Bank 在 6 月 5 日的研究报告中将礼来公司的股票评级从 “买入” 下调至 “持有”。汇丰全球研究在 4 月 28 日的研究报告中将礼来公司的股票评级从 “强力买入” 下调至 “适度卖出”。华尔街 Zen 在 7 月 26 日的报告中将礼来公司的股票评级从 “持有” 上调至 “买入”。Leerink Partners 在 8 月 7 日的报告中重申了 “市场表现” 评级，并对礼来公司的股票设定了 715.00 美元的目标价格。最后，Cantor Fitzgerald 在 4 月 22 日的报告中开始覆盖礼来公司的股票。他们给予了 “增持” 评级，并设定了 975.00 美元的目标价格。一位研究分析师对该股票给予了卖出评级，五位分析师给予了持有评级，十六位分析师给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 973.71 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 LLY 的最新研究报告</strong></p>
</div><h2>Eli Lilly and Company Trading Up 0.8%</h2>
<div class="lb-trans"><h2>礼来公司股价上涨 0.8%</h2>
</div><ul>
<li>Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来公司 14% 的财报后下滑是否是买入机会？</li>
</ul>
</div><p>LLY stock opened at $644.86 on Wednesday. The company's 50-day simple moving average is $769.64 and its 200-day simple moving average is $797.19. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.53. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market cap of $610.33 billion, a P/E ratio of 42.30, a PEG ratio of 0.89 and a beta of 0.44.</p>
<div class="lb-trans"><p>礼来公司的股票在周三开盘价为 644.86 美元。该公司的 50 日简单移动平均线为 769.64 美元，200 日简单移动平均线为 797.19 美元。礼来公司的 52 周低点为 623.78 美元，52 周高点为 972.53 美元。该公司的速动比率为 1.00，流动比率为 1.28，债务股本比率为 1.86。该公司的市值为 6103.3 亿美元，市盈率为 42.30，PEG 比率为 0.89，贝塔值为 0.44。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the firm earned $3.92 EPS. The business's revenue was up 37.6% compared to the same quarter last year. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最后一次公布季度财报是在 8 月 7 日。该公司报告每股收益（EPS）为 6.31 美元，超出分析师的共识预期 5.59 美元，超出幅度为 0.72 美元。礼来公司的净利润率为 25.91%，股本回报率为 92.72%。该公司在本季度的收入为 155.6 亿美元，而共识预期为 144.0 亿美元。去年同期，该公司每股收益为 3.92 美元。与去年同期相比，该公司的收入增长了 37.6%。整体来看，股票分析师预测礼来公司在当前财政年度将发布 23.48 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><ul>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德股票下跌——但底部是否终于到来？</li>
</ul>
</div><p>In other news, Director J Erik Fyrwald acquired 1,565 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.14% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 J Erik Fyrwald 在 8 月 12 日的交易中购买了 1565 股该公司的股票。该股票的平均购买价格为每股 642.33 美元，总价值为 1,005,246.45 美元。交易完成后，该董事直接持有 74,578 股该公司的股票，价值约为 47,903,686.74 美元。这笔交易代表了他们持股比例的 2.14% 的增加。该收购在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，执行副总裁 Daniel Skovronsky 在 8 月 12 日的交易中购买了 1000 股该公司的股票。该股票的平均购买成本为每股 634.40 美元，总价值为 634,400.00 美元。收购后，该执行副总裁直接持有 137,660 股该公司的股票，价值约为 87,331,504 美元。这笔交易使他们的持股比例增加了 0.73%。该购买的披露信息可以在此找到。在过去 90 天内，内部人士共购买了 4,514 股公司股票，价值为 2,894,841 美元。目前，0.14% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Eli Lilly and Company</h2>
<div class="lb-trans"><h2>礼来公司的机构交易情况</h2>
</div><p>Several large investors have recently modified their holdings of LLY. Tobias Financial Advisors Inc. boosted its holdings in Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock worth $237,000 after acquiring an additional 12 shares during the last quarter. Redwood Investments LLC raised its stake in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock worth $1,705,000 after purchasing an additional 12 shares during the period. Hobbs Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC raised its stake in shares of Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after purchasing an additional 12 shares during the period. Finally, O Brien Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近调整了他们在 LLY 的持股。Tobias Financial Advisors Inc.在第四季度将其在礼来公司的持股增加了 4.1%。Tobias Financial Advisors Inc.目前持有 307 股该公司的股票，价值 237,000 美元，此前在上个季度增加了 12 股。Redwood Investments LLC 在第四季度将其在礼来公司的持股增加了 0.5%。Redwood Investments LLC 目前持有 2209 股该公司的股票，价值 1,705,000 美元，此前在此期间购买了 12 股。Hobbs Wealth Management LLC 在第一季度将其在礼来公司的持股增加了 0.8%。Hobbs Wealth Management LLC 目前持有 1459 股该公司的股票，价值 1,205,000 美元，此前在此期间购买了 12 股。Hixon Zuercher LLC 在第一季度将其在礼来公司的持股增加了 0.7%。Hixon Zuercher LLC 目前持有 1789 股该公司的股票，价值 1,477,000 美元，此前在此期间购买了 12 股。最后，O Brien Wealth Partners LLC 在第一季度将其在礼来公司的持股增加了 25.5%。O Brien Wealth Partners LLC 目前持有 59 股该公司的股票，价值 49,000 美元，此前在此期间购买了 12 股。机构投资者和对冲基金持有该公司 82.53% 的股票。</p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Data Centers in Demand—This REIT Owns a Whole Portfolio</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>3 Battery Stocks to Buy and Hold for the Rest of the Decade</li>
<li>What is a Microcap Stock? Everything You Need to Know</li>
<li>3 Stocks to Consider as Tension Builds in Energy Markets</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比礼来公司更好的股票</li>
<li>REIT 股票 - 今天值得加入您投资组合的最佳 REIT 股票</li>
<li>数据中心需求旺盛——这家 REIT 拥有整个投资组合</li>
<li>3 只引领迷因股复兴的股票</li>
<li>3 只值得在未来十年内买入并持有的电池股票</li>
<li>什么是微型股？您需要知道的一切</li>
<li>在能源市场紧张局势加剧时值得考虑的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑礼来公司之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

古根海姆将礼来公司（NYSE:LLY）的目标股价下调至 875.00 美元